Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.73M Buy
24,121
+80
+0.3% +$27.4K 1.96% 7
2026
Q1
$8.46M Buy
24,041
+107
+0.4% +$38.1K 2.11% 8
2025
Q4
$7.83M Buy
23,934
+1,220
+5% +$387K 1.93% 9
2025
Q3
$6.41M Sell
22,714
-369
-2% -$107K 1.65% 12
2025
Q2
$6.45M Buy
23,083
+44
+0.2% +$12.5K 1.72% 10
2025
Q1
$7.18M Buy
23,039
+803
+4% +$237K 2.08% 9
2024
Q4
$5.8M Sell
22,236
-456
-2% -$135K 1.73% 9
2024
Q3
$7.31M Buy
22,692
+485
+2% +$159K 2.22% 8
2024
Q2
$6.94M Sell
22,207
-400
-2% -$118K 2.26% 7
2024
Q1
$6.43M Sell
22,607
-275
-1% -$80.5K 2.18% 8
2023
Q4
$6.59M Buy
22,882
+870
+4% +$237K 2.44% 6
2023
Q3
$5.92M Buy
22,012
+710
+3% +$177K 2.68% 6
2023
Q2
$4.73M Buy
21,302
+2,573
+14% +$597K 2.12% 8
2023
Q1
$4.53M Buy
18,729
+75
+0.4% +$18.4K 2.3% 6
2022
Q4
$4.9M Buy
18,654
+33
+0.2% +$8.85K 2.63% 5
2022
Q3
$4.2M Sell
18,621
-125
-0.7% -$30.3K 2.45% 5
2022
Q2
$4.56M Sell
18,746
-130
-0.7% -$31.9K 2.52% 5
2022
Q1
$4.56M Buy
18,876
+1,785
+10% +$410K 2.19% 9
2021
Q4
$3.84M Buy
+17,091
New +$3.61M 1.92% 11

Other funds holding AMGN

Brown, Lisle/Cummings's AMGN Position: Q2 2026 in Review

Brown, Lisle/Cummings increased its Amgen (AMGN) stake by 0.33% in Q2 2026, buying an estimated $27.4K and bringing the position to 24,121 shares worth $8.73M. The position accounts for 1.96% of the portfolio, ranked #7.

Brown, Lisle/Cummings first reported a position in AMGN in Q4 2021 and has held it in 19 quarters since. 3,149 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Brown, Lisle/Cummings held 24,121 shares of Amgen worth $8.73M as of Q2 2026.
  • Brown, Lisle/Cummings bought 80 Amgen shares in Q2 2026, an estimated $27.4K.
  • Amgen made up 1.96% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #7 holding.
  • Brown, Lisle/Cummings first reported a position in Amgen in Q4 2021 and has held it in 19 quarters since.
  • 3,149 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.